Leptin is the hormone that tells the brain the body has enough fat. When it works, eating produces satiety. When it doesn't — a state called leptin resistance — the brain ignores the signal, and appetite persists regardless of energy stores. Leptin resistance accompanies most forms of obesity. For thirty years, the assumption was that chronic overnutrition permanently damages the leptin signaling pathway. The receptors degrade. The neurons stop responding. The resistance is structural.
It isn't.
Researchers found that leptin resistance in diet-induced obese mice is caused by hyperactive mTOR in hypothalamic POMC neurons. mTOR — a kinase pathway that senses nutrient availability — becomes constitutively active, blocking the downstream signaling cascade (POMC to α-MSH to MC4R) that translates leptin into satiety. The pathway isn't broken. It's stuck in the “fed” position.
Rapamycin, an mTOR inhibitor already in clinical use for transplant rejection and some cancers, reverses the resistance. Treated mice regained leptin sensitivity, reduced food intake, and lost weight — specifically fat mass, not lean tissue. The reversal worked only when the downstream melanocortin pathway was intact, confirming that mTOR hyperactivity is the bottleneck, not a symptom.
The distinction matters therapeutically. Permanent damage requires regeneration or replacement. A stuck switch requires an inhibitor. The thirty-year search for what leptin resistance destroyed was looking for the wrong kind of lesion. Nothing was destroyed. The pathway was intact, its gate jammed open by the very nutrients it was designed to sense. The sensor was blinded by its own input.